MET and neoplasm: Merestinib (LY2801653) is an orally bioavailable, type II MET kinase inhibitor, with a slow binding off-rate, and has demonstrated anti-tumor and anti-angiogenic activity in several MET amplified and MET autocrine xenograft tumor models [14, 15].